Literature DB >> 6834008

Antigenic sites on the CVS rabies virus glycoprotein: analysis with monoclonal antibodies.

M Lafon, T J Wiktor, R I Macfarlan.   

Abstract

Antigenic variation in the glycoprotein of rabies (CVS-11) virus was studied. Neutralization-resistant variant viruses were isolated in vitro at high frequency (10(-4) to 10(-5)) in the presence of anti-glycoprotein monoclonal antibody. Analysis of these variants identified at least three functionally independent antigenic sites, based on the grouping of variants that were no longer neutralized by one or more of a panel of 24 monoclonal antibodies. Competition radioimmunoassay suggested that one of these three antigenic sites was topologically distinct, with the other two in close proximity. In addition, it was shown that most (but not all) neutralization-resistant variants failed to bind the relevant monoclonal antibody. Viruses with altered antigenicity were shown to accumulate in virus stocks following several passages in vitro in the absence of antibody. In addition, variants were isolated in vivo following treatment of mice with monoclonal antibody.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6834008     DOI: 10.1099/0022-1317-64-4-843

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  37 in total

1.  Antigenic variation of the bovine ephemeral fever virus glycoprotein.

Authors:  D H Cybinski; S S Davis; H Zakrzewski
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

2.  Raccoon poxvirus recombinants expressing the rabies virus nucleoprotein protect mice against lethal rabies virus infection.

Authors:  D L Lodmell; J W Sumner; J J Esposito; W J Bellini; L C Ewalt
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

3.  Structural and immunological characterization of a linear virus-neutralizing epitope of the rabies virus glycoprotein and its possible use in a synthetic vaccine.

Authors:  B Dietzschold; M Gore; D Marchadier; H S Niu; H M Bunschoten; L Otvos; W H Wunner; H C Ertl; A D Osterhaus; H Koprowski
Journal:  J Virol       Date:  1990-08       Impact factor: 5.103

4.  Antigenicity of rabies virus glycoprotein.

Authors:  A Benmansour; H Leblois; P Coulon; C Tuffereau; Y Gaudin; A Flamand; F Lafay
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

5.  Rabies virus infects mouse and human lymphocytes and induces apoptosis.

Authors:  M I Thoulouze; M Lafage; J A Montano-Hirose; M Lafon
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

6.  Rabies virulence: effect on pathogenicity and sequence characterization of rabies virus mutations affecting antigenic site III of the glycoprotein.

Authors:  I Seif; P Coulon; P E Rollin; A Flamand
Journal:  J Virol       Date:  1985-03       Impact factor: 5.103

7.  Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants.

Authors:  Alexander B H Bakker; Wilfred E Marissen; R Arjen Kramer; Amy B Rice; William C Weldon; Michael Niezgoda; Cathleen A Hanlon; Sandra Thijsse; Harold H J Backus; John de Kruif; Bernhard Dietzschold; Charles E Rupprecht; Jaap Goudsmit
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

8.  Epitopes of herpes simplex virus type 1 glycoprotein gC are clustered in two distinct antigenic sites.

Authors:  S D Marlin; T C Holland; M Levine; J C Glorioso
Journal:  J Virol       Date:  1985-01       Impact factor: 5.103

9.  Hemagglutinin-neuraminidase glycoprotein as a determinant of pathogenicity in mumps virus hamster encephalitis: analysis of mutants selected with monoclonal antibodies.

Authors:  A Löve; R Rydbeck; K Kristensson; C Orvell; E Norrby
Journal:  J Virol       Date:  1985-01       Impact factor: 5.103

10.  Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans.

Authors:  Thomas Müller; Bernhard Dietzschold; Hildegund Ertl; Anthony R Fooks; Conrad Freuling; Christine Fehlner-Gardiner; Jeannette Kliemt; Francois X Meslin; Richard Franka; Charles E Rupprecht; Noël Tordo; Alexander I Wanderler; Marie Paule Kieny
Journal:  PLoS Negl Trop Dis       Date:  2009-11-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.